Frederick R. Appelbaum, M.D. Fred Hutchinson Cancer Research Center Seattle, WA
Dr. Appelbaum received his medical degree from Tufts University Medical School in Boston. He is currently Director, Division of Clinical Research and Senior Vice President, the Fred Hutchinson Cancer Research Center, Seattle, WA. He also serves as Chairman of the National Cancer Institute's Board of Scientific Advisors, as well as on the National Cancer Institute's Advisory Committee to the Director. He is on the editorial boards of more than 12 prestigious medical journals, including American Journal of Hematology, Cancer Research, Blood and Leukemia Research. Dr. Applebaum has published more than 300 papers in peer-reviewed journals on leukemia therapies and bone marrow transplantation.
James R. Downing, M.D. St. Jude Children's Research Hospital Memphis, TN
The major themes of Dr. Downing's research are the role of chromosomal translocations in the pathogenesis of pediatric malignancies and the use of these discoveries in the diagnosis and management of pediatric patients. He received his medical degree from the University of Michigan, School of Medicine.
D. Gary Gilliland, M.D., Ph.D. Harvard Medical School and Howard Hughes Medical Institute Boston, MA
Dr. Gilliland is Associate Professor of Medicine at Harvard Medical School and an Associate Investigator at the Howard Hughes Medical Institute. He received his doctorate from the University of California, Los Angeles and his medical degree from he University of California, San Francisco. Dr. Gilliland currently serves on the editorial boards of Blood, Leukemia Research and is the Associate Editor and Section Chief of Oncogenesis of The Hematology Journal. He has published many scholarly articles on genes that are altered and disrupted in leukemia and their role in leukemogenesis.
Mitchell Kronenberg, Ph.D. LaJolla Institute for Allergy & Immunology San Diego, CA
Dr. Kronenberg received his doctorate from the California Institute of Technology and is currently a Member and Division Head at the LaJolla Institute of Allergy and Immunology. Dr. Kronenberg has isolated and studied the role of numerous genes involved in immune function. He is an Associate Editor of the Journal of Immunology and is a member of the editorial board of Cellular Immunity, Immunogenetics and Immunology Letters.
Ihor R. Lemischka, Ph.D. Princeton University Princeton, NJ
Dr. Lemischka is a leader in the field of hematopoietic and totipotent stem cell research. He is Associate Professor of Molecular Biology at Princeton University. Dr. Lemischka is an associate editor of the journal Immunity and a member of the National Institutes of Health, Cardiovascular Sciences Integrated Review committee's Hematology sub committee.
Michael W. Long, Ph.D. University of Michigan Ann Arbor, MI
Dr. Long studies the role of cell cycle gene expression in cellular growth and the role of proteoglycans in hematopoietic cell adhesion, growth and cellular differentiation. Dr. Long received his doctorate from Wayne State University. He is a Member of the University of Michigan Cancer Center and Professor, Department of Pediatrics and Communicable Diseases. He is an editorial board member of the journal Blood.
W. Stratford May Jr., M.D., Ph.D. University of Florida Gainesville, FL
Dr. May is the Harry F. Innes Professor of Cancer Research and the Director of the Shands Cancer Center at the University of Florida. He received his doctorate from the Medical College of Virginia and his medical degree from Georgetown University, in Washington, DC. He is currently Chairman of the Leukemia & Lymphoma Society's Medical and Scientific Committee. Dr. May is a member of the National Institutes of Health's Hematology Study Section and is an editorial board member of the journal Blood. Dr. May has published extensively on the genes and proteins involved in growth and death signaling of blood cells.
Robert Negrin, M.D. Stanford University Stanford, CA
Dr. Negrin is the Associate Director, Division of Bone Marrow Transplantation, and Associate Professor of Medicine at Stanford University. He received his medical degree from Harvard University and further trained in medicine and hematology at Stanford University. He is a member of the American Society of Clinical Oncology Chemoprotectants Expert Panel. He serves on the editorial boards of Biology of Blood and Marrow Transplantation and Cytotherapy. Dr. Negrin's research focuses on the use of hematopoietic growth factors in stem cell transplantation.
Naomi Rosenberg, Ph.D. Tufts University School of Medicine Boston, MA
Dr. Rosenberg studies the role of oncogenes and tumor suppressor genes in the leukemogenic process. She is a member of the National Institutes of Health's Board of Scientific Counselors and Director of the Graduate Program in Genetics at Tufts University. Dr. Rosenberg received her doctorate from the University of Vermont and is currently Professor of Pathology and Professor of Molecular Biology at Tuft's University School of Medicine.
Kevin Shannon, M.D. University of California, San Francisco San Francisco, CA
Dr. Shannon is the Roma and Marvin Auerback Distinguished Professor of Molecular Oncology, Department of Pediatrics, The University of California, San Francisco. He received his medical degree at Cornell University Medical College. He is a member of the Children's Cancer Group and a member of the National Cancer Institute's Mouse Models of Human Cancer Consortium Steering Committee. Dr. Shannon has published numerous scientific papers on the structure, function and mutation of various genes involved in growth factor signaling in childhood leukemia. He has also been a leader in the use of genetically modified mice as a model for the study of pediatric and juvenile leukemias.
Cheryl L. Willman, M.D. University of New Mexico, Health Sciences Center Albuquerque, NM
Dr. Willman is Professor of Pathology at the University of New Mexico. Her research has produced advances in the understanding of acute myelogenous leukemia.
Owen N. Witte, M.D. Howard Hughes Medical Institute and University of California at Los Angeles Los Angeles, Ca
Dr. Witte is an Investigator of the Howard Hughes Medical Institute and The David Saxon Presidential Chair in Developmental Immunology. He is a member of the National Academy of Science and a past winner of the William Dameshek Prize of the American Society of Hematology. Dr. Witte is an expert in the field of growth signal transduction and its disruption in leukemia. He is a member of numerous editorial boards including, Cell, Leukemia, Developmental Immunology and the Journal of Clinical Investigation. Dr. Witte received his medical degree from Stanford University Medical School.
Nancy Berliner, M.D. Yale University School of Medicine New Haven, CT
Dr. Berliner is an Associate Professor of Internal Medicine and Genetics at Yale University School of Medicine. She is studying genes involved in the differentiation of myeloid cells and their role in leukemogenesis.
Richard Champlin, M.D. MD Anderson Cancer Center Houston, TX
Dr. Champlin is the Robert C. Hickey Chair of Clinical Cancer Care and Chair of the Department of Blood and Marrow Transplantation at the University of Texas-M.D. Anderson Cancer Center. He received his medical degree from the University of Chicago's Pritzker School of Medicine. Dr. Champlin is also a member of the Executive Board, The American Autologous Bone Marrow Transplant Registry. He serves on the editorial boards of Blood, Bone Marrow Transplantation, The Journal of Hematology and others. Dr. Champlin's research has advanced the fields of chemotherapy and bone marrow transplantation in the treatment of leukemia and lymphoma.
Michael Clarke, M.D. CCGC, Room 4310 Ann Arbor, MI
Dr. Clarke's research utilizes viral gene vectors to deliver pro-apoptotic genes to cancer cells. He is also investigating how the tumor suppressor, p53, functions in cancer cell drug resistance. Dr. Clarke received his medical degree from Indiana University and is currently a Professor, Department of Hematology and Oncology, University of Michigan.
Gary Dahl, M.D. Stanford University Medical Center Stanford, CA
Dr. Dahl is Professor, Department of Pediatrics, Division of Hematology/Oncology at Stanford University. He is also the Co-Director of the Oncology Program at the Lucille Packard Children's Hospital at Stanford University. Dr. Dahl received his medical degree from Oregon University Medical School. Dr. Dahl is a leader in new therapies for the treatment of childhood acute myeloid leukemia and is the Vice Chair of the Pediatric Oncology Group's Myeloid Disease Committee.
Stephen Emerson, M.D., Ph.D. University of Pennsylvania Philadelphia, PA
Dr. Emerson is Professor and Chief, Hematology-Oncology Division the University of Pennsylvania and Associate Director, Clinical Research, University of Pennsylvania Cancer Center. He received his both of his doctoral degrees from Yale University School of Medicine. Dr. Emerson has investigated the role of cytokines, growth factors and their signal transduction pathways in the regulation of normal and leukemic bone marrow cells. He is a member of the Blood editorial board.
Alan Gewirtz, M.D. University of Pennsylvania Philadelphia, PA
Dr. Gewirtz is a leader in the field of antisense drug therapies for the treatment of leukemia. He also studies the role of hematopoietic growth factors in stem cell growth and development. He received his medical degree from the State University of New York at Buffalo. He is presently Professor of Internal Medicine at the University of Pennsylvania School of Medicine and the Leader of the Stem Cell Biology and Therapeutics Program at the university's cancer center. He is an editor of Stem Cells and a member of the editorial board of numerous journals including Leukemia, Antisense Research and Drug Design, and Experimental Hematology.
Dr. Henderson is a past Professor of Medicine and Hematology Attending, VA Western New York Healthcare System. Dr. Henderson was Chief of the Leukemia and Lymphoma Service at Roswell Park Cancer Institute. He has served on numerous editorial boards and National Institutes of Health committees and study sections.
Barton A. Kamen, M.D, Ph.D. Robert Wood Johnson Medical Center New Brunswick, NJ
Dr. Kamen is Professor of Pediatrics and Director of Pediatric Hematology-Oncology at the University of New Jersey's, Robert Wood Johnson Medical School. Dr. Kamen's research has focused on new therapies for pediatric cancers, in particular the use of anti-folate therapies in pediatric leukemias and lymphomas. He is an editorial board member of many leading cancer therapy journals including, Journal of Clinical Oncology, Clinical Cancer Research, and Cancer Therapeutics. Dr. Kamen received both of his doctoral degrees from Case Western Reserve University.
Armand Keating, M.D. Princess Margaret Hospital Toronto, Canada
Dr. Keating is Director, Division of Hematology, and Professor of Medicine at the University of Toronto, Canada. He is also the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Toronto Hospital. He serves on several committees of the American Society for Blood and Marrow Transplantation. Dr. Keating also serves as co-editor of Bone Marrow Transplantation and Hematology. He has published many scholarly articles concerning stem cell transplantation, gene therapy and high dose therapies for acute myelogenous leukemia.
Charles Linker, M.D. University of California San Francisco, CA
Dr. Linker is a leader in developing new therapeutic regimens in the treatment of myeloid leukemias and in bone marrow transplantation. He is the Chair of the Transplant Committee of the Cancer and Leukemia Group B Co-operative Group. Dr. Linker is a Professor of Medicine and the Director of the Adult Leukemia and Bone Marrow Transplant Program at the University of California, San Francisco. He received his medical degree from Stanford University Medical School.
W Stratford May Jr., M.D., Ph.D. University of Florida Gainesville, FL
Dr. May is the Harry F. Innes Professor of Cancer Research and the Director of the Shands Cancer Center at the University of Florida. He received his Ph.D. from the Medical College of Virginia and his medical degree from Georgetown University in Washington, DC. He is currently the Chair of the Leukemia & Lymphoma Society's Medical and Scientific Committee. Dr. May is a member of the National Institutes of Health's Hematology Study Section and is an editorial board member of the journal Blood. Dr. May has published extensively on the genes and proteins involved in growth and death signaling of blood cells.
Ronald McCaffrey, M.D. Lowell General Hospital Lowell, MA
Dr. McCaffrey is the Director of the Lowell Hospital Cancer Center and Lecturer in Medicine at Harvard Medical School. He is a past member of the editorial board of Blood and currently a member of the Leukemia Research editorial board. His research has lead to a more complete understanding of the physiology of hematopoietic cells and their dysfunction in hematological malignancies.
Beverly S. Mitchell, M.D. University of North Carolina at Chapel Hill Chapel Hill, NC
Dr. Mitchell is Professor of Pharmacology and Internal Medicine and the Wellcome Distinguished Professor of Cancer Research. She is also, Chief, Division of Hematology/Oncology and the Associate Director, Lineberger Comprehensive Cancer Center's Molecular Therapeutics Program.
Richard O'Reilly, M.D. Memorial Sloan-Kettering Cancer Center New York, NY
Dr. O'Reilly is chairman of Bone Marrow Transplantation at Memorial Sloan-Kettering Cancer Institute, in New York City. He is co-editor of Biology of Blood and Marrow Transplantation. His research focuses on allogeneic hematopoietic cell transplantation the factors that lead to successful engraftment and development of the graft within an allogeneic human host.
Robertson Parkman, M.D. Children's Hospital Los Angeles, CA
Dr. Parkman is a Professor of Pediatrics and of Microbiology, University of Southern California. He is also Associate Director for Clinical Research, Children's Hospital, Los Angeles. He has published extensively on bone marrow transplantation and the use of gene therapy in transplantation. He received his medical degree from Yale University, where he also trained in Pediatrics.
David Poplack, M.D. Baylor College of Medicine Hematology/Oncology Section Houston, TX
Dr. Poplack is the Elise C. Young Professor of Pediatric Oncology and chairman, Hematology-Oncology Section, Department of Pediatrics, at Baylor College of Medicine. He is also Director of the Texas Children's Cancer Center. He is co-editor of Principles and Practice of Pediatric Oncology, the leading textbook of pediatric oncology, now in its third edition.
Peter Quesenberry, M.D. University of Massachusetts Medical Center Worcester, MA
Dr. Quesenberry is Professor of Medicine and Professor of Cell Biology, University of Massachusetts and the past Director of the University of Massachusetts' Cancer Center. He has explored the role of hematopoietic growth factors in bone marrow transplantation as well as the role of various cell cycle and cell adhesion genes in hematopoietic cell growth. He is a past editorial board member of numerous hematology journals and is currently a member of the International Journal of Hematology and the American Journal of Hematology editorial boards.
Joel Rappeport, M.D. Yale University School of Medicine New Haven, CT
Dr. Rappeport is one of the pioneers of bone marrow transplantation and leukemia therapeutics. He is a Professor of Medicine and a Professor of Pediatrics, Yale University School of Medicine. Dr. Rappeport is a member of two cancer cooperative groups, the Pediatric Oncology Group and the Eastern Clinical Oncology Group and has served as a medical advisor to many non-profit groups.
Charles Schiffer, M.D. Wayne University School of Medicine Detroit, MI
Dr. Schiffer received his medical degree from New York University School of Medicine and received further training at the National Cancer Institute. He is currently Chief, Division of Hematology/Oncology and Vice Chair for Cancer Affairs at Wayne State University. He is also Director of Clinical Research at the Karmanos Cancer Institute. He has served on many national and international clinical advisory committees and is a leukemia committee member of the of the Southwest Oncology Group. His research has contributed significantly to our understanding of chromosome rearrangements in leukemia and in the development of therapeutic modalities for the treatment of leukemia.
Stephen J. Schuster, M.D. University of Pennsylvania Cancer Center Philadelphia, PA
Dr. Schuster's research and treatment experience spans leukemias, lymphomas, myeloma and related disorders. He is a member of the Eastern Cooperative Oncology Group and is the Director, Lymphoma Program at the University of Pennsylvania Cancer Center. He received his medical degree from Jefferson Medical College.
Guido Tricot, M.D., Ph.D. University of Arkansas for Medical Sciences Little Rock, AK
Dr. Tricot received both his doctoral degrees from the University of Leuven, Belgium. He is a leader in the development of new therapeutic modalities for the treatment of multiple myeloma. Dr. Tricot is a Professor of Medicine and the Director, Myeloma Transplantation, at the University of Arkansas. He also serves as a member of the Leukemia editorial board.
Catherine M. Verfaillie, M.D. University of Minnesota Minneapolis, MN
Dr. Verfaillie received her medical degree from the University of Leuven Medical School, Leuven, Belgium. She is a member of several grant review committees including the National Institutes of Health's Hematology Study Section and the Veteran's Administration's Hematology Merit Review Panel. She is Associate Editor of Experimental Hematology and an editor of Leukemia. Dr. Verfallie is a Professor of Medicine and Director of the Stem Cell Biology Program at the University of Minnesota.
Edward Arnold, Ph.D. Rutgers University Piscataway, NJ
Dr. Arnold is Professor of Chemistry, Rutgers University. He received his doctorate from Cornell University. His research concerns x-ray crystallographic studies of viruses and viral proteins for design of antiviral agents and recombinant vaccines based on structural information. Dr. Arnold is active in reviewing research proposals and organizing scientific meetings including the Third International Workshop on HIV Drug Resistance.
Irwin Bernstein, M.D. Fred Hutchinson Cancer Research Center Seattle, WA
Dr. Bernstein is the John R. Hartman Endowed Chair in Pediatric Oncology/Hematology at Children's Hospital and Medical Center, Seattle Washington. He is also a Member of the Fred Hutchinson Cancer Research Center, Seattle, WA. His research has advanced our understanding of the genes and proteins involved in programmed cell death. He has also developed monoclonal antibody therapies for acute myeloid leukemia. Dr. Bernstein is editor of the Hematologic Malignancies series of Current Opinion in Hematology and an Associate Editor of Clinical Cancer Research.
David M. Bodine, Ph.D. National Institutes of Health Bethesda, MD
Dr. Bodine is Chief, the Hematopoiesis Section of the National Human Genome Research Institute of the National Institutes of Health. His research has focused on the use of viruses in hematopoietic stem cell gene therapy. He is a member of the editorial boards of Blood and Experimental Hematology.
Frances Brodsky, Ph.D. University of California, San Francisco San Francisco, CA
Dr. Brodsky is Professor of Biopharmaceutical Sciences, Immunology and Microbiology, and Pharmaceutical Chemistry. Her research tries to define the molecular control of intracellular membrane transport.
Hal E. Broxmeyer, Ph.D. Indiana University School of Medicine Indianapolis, IN
Dr. Broxmeyer is Chairman and the Mary Margaret Walther Professor of Microbiology and Immunology, and Scientific Director of Indiana University's Walther Oncology Center. Dr. Broxmeyer is a leader in the field of cord blood cell transplantation. He is a member of more than 15 editorial boards, including the International Journal of Hematology, the British Journal of Hematology and Current Trends in Immunology. He is an Associate Editor of Stem Cells. Dr. Broxmeyer received his doctorate from New York University.
John Coffin, Ph.D. Tufts University School of Medicine Boston, MA
Dr. Coffin is a leader in the field of RNA tumor viruses. He received his doctorate from the University of Wisconsin and was a professor at Tufts University before assuming the role of Director, HIV Drug Resistance Program, at the National Cancer Institute. He has served on numerous editorial boards. Dr. Coffin is a member of the National Academy of Science.
John Colicelli, Ph.D. University of California, Los Angeles Los Angeles, CA
Dr. Colicelli received his doctorate in biochemistry from Columbia University. He is currently an Associate Professor of Biological Chemistry, the University of California at Los Angeles School of Medicine. His research involves defining the physical and functional associations of various signal transduction proteins.
John W. Erickson, Ph.D. National Cancer Institute Frederick Cancer Research and Development Center Frederick, MD
Dr. Erickson studies the structural-functional relationships of anti-HIV drugs and their target proteins. He is the Director, Structural Biochemistry Program and Vice President of the National Cancer Institute's Frederick Cancer Research and Development Center. He is also Scientific Director at the Frederick Biomedical Supercomputing Center. He is a member of the editorial boards of the Journal of Molecular Recognition and Perspectives in Drug Discovery.
Hung Fan, Ph.D. University of California at Irvine Irvine, CA
Dr. Fan is Director, University of California, Irvine Cancer Research Institute, and Professor of Virology, Department of Molecular Biology and Biochemistry. His research uses RNA tumor viruses to understand the various molecular changes necessary for tumor formation. He has served on many National Institutes of Health grant review committees and advisory panels.
Richard Fishel, Ph.D. Kimmel Cancer Center Philadelphia, PA
Dr. Fishel is Program Leader, Genetics and Molecular Biology Program, and Professor of Microbiology and Immunology at the Kimmel Cancer Center, Thomas Jefferson University. The focus of Dr. Fishel's research is the genetics and biochemistry of human DNA repair and the genes/proteins that participate in DNA repair.
Judith Gasson, Ph.D. UCLA School of Medicine Los Angeles, CA
Dr. Gasson's research tries to understand the molecular and biochemical events linking proliferation and maturation of mammalian blood cells. She is Director of the Jonsson Comprehensive Cancer Center, and is Professor of Medicine and Biological Chemistry at the University of California, Los Angeles.
Katia Georgopoulos, Ph.D. Massachusetts General Hospital Charlestown, MA
Dr. Georgopoulos is an Associate Biologist in the Department of Dermatology, Massachusetts General Hospital. She studies the Ikaros gene, a gene that is important in the early development of lymphoid cells.
David Gorenstein, Ph.D. University of Texas Medical Branch Galveston, TX
Dr. Gorenstein's research uses biophysical techniques to understand the interaction of transcription factors and other DNA binding proteins with DNA. He is Director, Sealy Center for Structural Biology, and is the Charles Marc Pomerut Distinguished Professor of Biological Sciences, the University of Texas Medical Branch, Galveston. He is an editorial board member of the Journal of Magnetic Resonance and the Biophysical Journal. In 1994, Dr. Gorenstein was elected a Fellow of the American Association for the Advancement of Science.
Eric Hendrickson, Ph.D. Brown University Providence, RI
Dr. Hendrickson is an Associate Professor of Biology at Brown University. He received his doctorate from Harvard University. His research examines DNA damage and its role in apoptosis.
Michael B. Kastan, M.D., Ph.D. St. Jude Children's Research Hospital Memphis, TN
Dr. Kastan is Chairman, Department of Hematology/Oncology, at St. Jude Children's Research Hospital. He is a member of the National Cancer Institute Board of Scientific Counselors and a member of the American Association for Cancer Research Board of Directors. His research examines the mechanism of tumor suppressor gene function and the mechanisms of apoptosis.
Paul W. Kincade, Ph.D. Oklahoma City Medical Research Foundation Oklahoma City, OK
Dr. Kincade is a leader in the field of stromal cell modulation of lymphocyte cell development and apoptosis. His most recent research explores the role of estrogen in B lymphocyte differentiation. He is Professor and Chairman of the Immunobiology and Cancer Program at Okalahoma Medical Research Foundation. Dr. Kincade is Associate Editor of Immunology Today and is a member of the editorial board of Cell Adhesion and Communications.
Ilan Kirsch, M.D. National Cancer Institute Bethesda, MD
Dr. Kirsch is Chairman, Acquired Gene Rearrangements Section, Navy Medical Oncology Branch, the National Cancer Institute, National Institutes of Health. He is an editorial board member of the Journal of the National Cancer Institute. He has been a leader in the cloning and functional study of genes that are rearranged in pediatric leukemias. He received his degree from Harvard.
Michelle Le Beau, Ph.D. University of Chicago Chicago, IL
Dr. LeBeau is Professor, Department of Medicine, Section of Hematology/Oncology, at the University of Chicago. Her research seeks to identify the recurring chromosomal abnormalities in human tumors and to identify the genes located at the breakpoints of the recurring abnormalities using the techniques of molecular genetics.
Michael Lenardo, M.D. National Institutes of Health Bethesda, MD
Dr. Lenardo is Section Head, Molecular Development of the Immune System Section of the National Institute of Allergy and Infectious Diseases. His research examines how the human immunodeficiency virus (HIV) causes the death of CD4 T lymphocytes.
Edith Lord, Ph.D. University of Rochester Medical Center Rochester, NY
Dr. Lord is Professor of Microbiology and Immunology at the University of Rochester. Her research focuses on immune responses that control tumor development.
W. Stratford May Jr., M.D., Ph.D. University of Florida Gainesville, FL
Dr. May is the Harry F. Innes Professor of Cancer Research and the Director of the Shands Cancer Center at the University of Florida. He received his doctorate from the Medical College of Virginia and his medical degree from Georgetown University in Washington, DC. He is currently Chairman of the Leukemia & Lymphoma Society's Medical and Scientific Committee. Dr. May is a member of the National Institutes of Health's Hematology Study Section and is an editorial bard member of the journal Blood. Dr. May has published extensively on the genes and proteins involved in growth and death signaling of blood cells.
John Monroe, Ph.D. University of Pennsylvania Medical Center Philadelphia, PA
Dr. Monroe is Professor, Pathology and Laboratory Medicine and Chairman, Immunology Graduate at the University of Pennsylvania. His research is the study of B lymphocyte activation and tolerance and the mechanisms of signal transduction through the B lymphocyte antigen receptor.
Ann Marie Pendergast, Ph.D. Duke University Medical Center Durham, NC
Dr. Pendergast's research has elucidated several factors that bind to and function within the abl gene pathway. She is an Associate Professor, Department of Pharmacology and Cancer Biology, Duke University. She is a member of the Cell Growth and Differentiation and Apoptosis editorial boards.
Jasper Rine, Ph.D. University of California, Berkeley Berkeley, CA
Dr. Rine is Director, Human Genome Center at the Lawrence Berkeley Labs, and is Professor of Genetics, the University of California at Berkeley. He is a member of the Genetics and Genome Biology editorial boards. Dr. Rine's research has significantly contributed to the understanding of DNA replication and gene expression.
Steven Rosen, M.D. Robert H. Lurie Cancer Center Chicago, IL
Dr. Rosen is the Genevieve Teuton Professor of Medicine at Northwestern University Medical School and Director of the Robert H. Lurie Comprehensive Cancer Center. He is editor of Cancer Treatment and Research and Chairman of the Laboratory Science Committee of the Eastern Cooperative Oncology Group.
Naomi Rosenberg, Ph.D. Tufts University School of Medicine Boston, MA
Dr. Rosenberg studies the role of oncogenes and tumor suppressor genes in the leukemogenic process. She is a member of the National Institutes of Health's Board of Scientific Counselors and Director of the Graduate Program in Genetics at Tufts University. Dr. Rosenberg received her doctorate from the University of Vermont and is currently Professor of Pathology and Professor of Molecular Biology at Tufts University School of Medicine.
Martine F. Roussel, Ph.D. St. Jude Children's Research Hospital Memphis, TN
Dr. Roussel is a Member, Department of Tumor Biology at St. Jude Children's Research Hospital. She has made several seminal discoveries in the mechanisms of cell cycle regulation. She is an associate editor of Cell Growth and Differentiation as well as a past member of the Molecular and Cellular Biology editorial board. Dr. Roussel received her doctorate from the University of Lille, France.
Christopher Rudd, Ph.D. Dana-Farber Cancer Institute Boston, MA
Dr. Rudd is an Associate Professor of Pathology, Harvard Medical School. He is an Associate Editor of the Journal of Immunology and a member of several federal review panels and study sections. His research is directed at understanding the signal transduction pathways involved in immune cell function. Dr. Rudd received his doctorate from University College, London.
Saul Sharkis, Ph.D. Johns Hopkins University school of Medicine Baltimore, MD
Dr. Sharkis received his doctorate from New York University. He is currently Professor of Oncology at Johns Hopkins University School of Medicine. His research has focused on the differentiation of hematopoietic stem cells. He is an editorial board member of the journals Stem Cells and Blood.
Jeffrey Sklar, M.D., Ph.D. Brigham and Women's Hospital Boston, MA
Dr. Sklar is a Professor of Pathology at Brigham and Women's Hospital. His major theme of research is the molecular biology of hematological cancer and growth control.
Nancy Speck, Ph.D. Dartmouth Medical School Hanover, NH
Dr. Nancy Speck is an Associate Professor of Biochemistry, Dartmouth Medical School. She has studied several transcription factors and their roles in hematopoiesis and leukemogenesis. Dr. Speck is an editorial board member of Virology and Journal of Virology.
Samuel Speck, Ph.D. Washington University St Louis, MO
Dr. Samuel Speck is an Associate Professor in the departmenta of Pathology and Immunology, and Molecular Microbiology, Washington University. His research focuses on two herpesviruses, Epstein-Barr virus (EBV) and murine gamma herpesvirus 68 and on identifying gHV68 genes involved in establishing and maintaining viral latency.
Ivan Stamenkovic, M.D. Massachusetts General Hospital Charlestown, MA
Dr. Stamenkovic is an Associate Professor of Pathology, Harvard Medical School, and is Director, Molecular Pathology Unit School, at Massachusetts General Hospital. His research has lead to a greater understanding of the genes and proteins involved in immune cell interactions and their role in metastasis when expressed in other tumor types. Dr. Stamenkovic received his medical degree from the University of Geneva School of Medicine, Switzerland.
Philip Tsichlis, Ph.D. Jefferson University Philadelphia, PA
Dr. Tsichlis received his medical degree from the University of Athens Medical School. His current research has elucidated the function several proteins important in apoptotic signaling and cell growth regulation. He is an editorial board member of the Journal of Virology and Archives of Biochemistry and Biophysics.
Michael D. Tyers, M.D. Lunerfeld Res. Institute Toronto, ON MSG 1X5,
Dr. Tyers is Professor, Department of Medical Genetics and Microbiology at the University of Toronto. He is a past winner of the Canadian Society of Biochemistry and Molecular Biology Merck-Frosst Award and the National Cancer Institute of Canada's Eli Lilly/William E. Rawls Prize. Dr. Tyers research examines cell cycle regulation in yeast.
Inder Verma, Ph.D. The Salk Institute San Diego, CA
Dr. Verma is a Professor of Biology and Director, Laboratory of Genetics at the Salk Institute. He is President of the American Society of Gene Therapy and his research focuses on the regulation of oncogenes and human gene therapy.
Karen Vousden, Ph.D. National Cancer Institute's Frederick Cancer Research and Development Center Frederick, MD
Dr. Vousden is Laboratory Director, Molecular Virology and Carcinogenesis at the National Cancer Institute's Frederick Cancer Research and Development Center. Her research has focused on several tumor suppressor genes and their roles in apoptosis and cellular growth regulation. Dr. Vousden is an editorial board member of Molecular and Cellular Biology and Oncogene. She received her doctorate from the University of London.
Jerry L. Workman, Ph.D. Pennsylvania State University State College, PA
Dr. Workman is the Paul Berg Professor of Biochemistry, at The Pennsylvania State College and is an Associate Investigator of the Howard Hughes Medical Institute. He is a leader in the field of chromatin and its role in gene regulation and is Editor of Molecular and Cellular Biology. Dr. Workman received his doctorate from The University of Michigan.
Michael Caligiuri, M.D. Ohio State University Columbus, OH
Dr. Caligiuri received his medical degree from Stanford University. He is currently the John L. Marakas Foundation Chair in Cancer Research, Co-Director, Division of Hematology and Oncology, and Associate Director for Clinical Cancer Research at Ohio State University. He is a member of the editorial boards of several journals, including the Journal of Clinical Immunology and Clinical Cancer Research. Dr. Caligiuri's research concerns the use of cytokines in modulating the activity of immune cells.
Curt I. Civin, M.D. Johns Hopkins Comprehensive Cancer Center Baltimore, MD
Dr. Civin is Professor of Oncology and Pediatrics and Director, Pediatric Oncology Service, at The Johns Hopkins University School of Medicine. He received his medical degree from Harvard Medical School. He has been a past member of numersous editorial boards, including Blood and Clincal Cancer Research and currently serves as Editor of Stem Cells. His research focuses on the use of stem cells in hematopoietic transplantation.
James D. Griffin, M.D. Dana Farber Cancer Institute Division of Hematologic Malignancies Boston, MA
Dr. Griffin is Pofessor of Medicine, Harvard Medical School, and is Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center. Dr. Griffin has pursued research on the genes and proteins involved in growth signal transduction and their alteration in leukemia. Dr. Griffin is a member of the Leukemia, Hemtologyical Oncology and British Journal of Hematology editorial boards. He is a past Editor-in-Chief of Blood.
Judith E. Karp, M.D. University of Maryland Greenbaum Cancer Center Baltimore, MD
Dr. Karp is Professor of Medicine and Oncology at the Marlene and Stewart Greenebaum Cancer Center, University of Maryland. Her recent research has focused on AIDS-related lymphoma. Dr. Karp has been the recipient of the National Institutes of Health Director's Award and a National Cancer Institute's Special Achievement Award. She is a member of the Experimental Hematology editorial board.
W. Stratford May Jr., M.D., Ph.D. University of Florida Shands Cancer Center Gainesville, FL
Dr. May is the Harry F. Innes Professor of Cancer Research and the Director of the Shands Cancer Center at the University of Florida. He received his doctorate from the Medical College of Virginia and his medical degree from Georgetown University in Washington, DC. He is currently chairman of the Leukemia & Lymphoma Society's Medical and Scientific Committee. Dr. May is a member of the National Institutes of Health's Hematology Study Section and is an editorial board member of the journal Blood. Dr. May has published extensively on the genes and proteins involved in growth and death signaling of blood cells.
Pier P. Pandolfi, M.D., Ph.D. Memorial Sloan-Kettering Cancer Research Center New York, NY
Dr. Pandolfi's research interests are inn the therapeutic targeting of transcription in acute leukemias. He is an Associate Member of the Department of Human Genetics at Memorial Sloan-Kettering Cancer Center and an Associate Professor of Molecular Biology and Human Genetics. Dr. Pandolfi is a editorial board member of the Journal of Hematology.
David Poplack, M.D. Baylor College of Medicine Hematology/Oncology Section Houston, TX
Dr. Poplack is the Elise C. Young Professor of Pediatric Oncology and chairman, Hematology-Oncology Section, Department of Pediatrics, at Baylor College of Medicine. He is also Director of the Texas Children's Cancer Center. He is co-editor of Principles and Practice of Pediatric Oncology, the leading textbook of pediatric oncology, now in its third edition.
The Leukemia & Lymphoma SocietyŽ (LLS) is the world's largest voluntary health
agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma,
Hodgkin's disease and myeloma, and improve the quality of life of patients
and their families. LLS funds lifesaving blood cancer research around the
world and provides free information and support services.
Need Help? Contact us by email,
mail,
or call (800) 955-4572
print page
email page
